Earlier this week, it was announced that injections of the Johnson & Johnson (NYSE:JNJ) COVID-19 vaccine would be paused, due to six cases of a rare type of blood clot. The company's single-dose vaccine also had its rollout in the EU delayed, and was paused in South Africa as well. Fortunately, as of April 14, almost a quarter of the U.S. population was fully vaccinated, and around 40% of the population had received at least one dose. As of the same date, according to a White House briefing, the J&J vaccine had accounted for fewer than 5% of the over 190 million recorded doses in the U.S.